{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:56:06Z","timestamp":1792173366157,"version":"4.4.0"},"reference-count":77,"publisher":"Korean Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes, Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["R01 DK128289"],"award-info":[{"award-number":["R01 DK128289"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-dmj.org"],"crossmark-restriction":true},"short-container-title":["Diabetes Metab J"],"published-print":{"date-parts":[[2024,3,31]]},"abstract":"<jats:p>Metabolic dysfunction-associated steatotic (fatty) liver disease (MASLD), previously termed non-alcoholic fatty liver disease, is a worldwide epidemic that can lead to hepatic inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The disease is typically a component of the metabolic syndrome that accompanies obesity, and is often overlooked because the liver manifestations are clinically silent until late-stage disease is present (i.e., cirrhosis). Moreover, Asian populations, including Koreans, have a higher fraction of patients who are lean, yet their illness has the same prognosis or worse than those who are obese. Nonetheless, ongoing injury can lead to hepatic inflammation and ballooning of hepatocytes as classic features. Over time, fibrosis develops following activation of hepatic stellate cells, the liver\u2019s main fibrogenic cell type. The disease is usually more advanced in patients with type 2 diabetes mellitus, indicating that all diabetic patients should be screened for liver disease. Although there has been substantial progress in clarifying pathways of injury and fibrosis, there no approved therapies yet, but current research seeks to uncover the pathways driving hepatic inflammation and fibrosis, in hopes of identifying new therapeutic targets. Emerging molecular methods, especially single cell sequencing technologies, are revolutionizing our ability to clarify mechanisms underlying MASLD-associated fibrosis and HCC.<\/jats:p>","DOI":"10.4093\/dmj.2023.0240","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T08:21:34Z","timestamp":1706257294000},"page":"161-169","update-policy":"https:\/\/doi.org\/10.4093\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome"],"prefix":"10.4093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1178-6195","authenticated-orcid":true,"given":"Scott L.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2567","reference":[{"key":"ref1","volume-title":"","author":"Feingold","year":"2000"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.12.053"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0055-0"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.06.022"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7570\/jomes22021"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2022.0444"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260477"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1519"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.11.019"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000329"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cld.930"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.027"},{"key":"ref15","first-page":"771","volume-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","author":"Lazarus","year":"2022"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000375"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"ref19","first-page":"463","volume-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","author":"Huang","year":"2023"},{"key":"ref20","volume-title":"American Diabetes Association releases a guideline update in NAFLD (non-alcoholic fatty liver disease) and diabetes"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000323"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.03.042"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.07.049"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2022.12.010"},{"key":"ref25","first-page":"2542","volume-title":"Metabolic dysfunction-associated fatty liver disease and subsequent development of adverse pregnancy outcomes","author":"Lee","year":"2022"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04536-0"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.012"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062126"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.867940"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adc9653"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk0855"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.005"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.056"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02016-6"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.311"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2006.08.017"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.020"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.01.040"},{"key":"ref40","first-page":"761","volume-title":"A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation","author":"Vujkovic","year":"2022"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.12.025"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.003"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1172\/jci162513"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.06.020"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.34221"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.013"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.038"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.03.041"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326874"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25889"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32475"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2029349"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16100"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.018"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31750"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.38"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.06.036"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00821-z"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.4161\/cc.23549"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2403-9"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.06.004"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05289-6"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add3949"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.100841"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00754-7"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.07.019"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.024"},{"key":"ref68","first-page":"450","volume-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","author":"Pfister","year":"2021"},{"key":"ref69","first-page":"468","volume-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","author":"Marcellin","year":"2013"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.09.065"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.06.006"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19569"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32358"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.03.021"},{"key":"ref75","first-page":"eabo4474","volume-title":"Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease","author":"Fujiwara","year":"2022"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1186\/1755-1536-5-s1-s26"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119964109"}],"container-title":["Diabetes &amp; Metabolism Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2023-0240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2023.0240","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2023-0240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T07:44:55Z","timestamp":1711698295000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2023.0240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,31]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.4093\/dmj.2023.0240","relation":{},"ISSN":["2233-6079","2233-6087"],"issn-type":[{"value":"2233-6079","type":"print"},{"value":"2233-6087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,31]]},"assertion":[{"value":"2023-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-26","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}